Poniard Pharmaceuticals Receives FDA Fast Track Designation For Picoplatin For Treatment Of Small Cell Lung Cancer (Medical News Today)
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, picoplatin, for the second-line treatment of refractory or resistant small cell lung cancer (SCLC). [click link for full article]

Giving Flamel a Generic Bum's Rush (The Motley Fool)
A trio of generic drug companies announces FDA approval of their versions of the blockbuster drug Coreg.